These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 171564

  • 1. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W, Kremer GJ, Müller D.
    MMW Munch Med Wochenschr; 1975 Oct 31; 117(44):1783-6. PubMed ID: 171564
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].
    Gaertner U, Johannes KJ.
    MMW Munch Med Wochenschr; 1976 Sep 03; 118(36):1127-30. PubMed ID: 184377
    [Abstract] [Full Text] [Related]

  • 4. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R, Müller A, Klose G, Middelhoff G, Augustin J, Haase W, Greten H.
    MMW Munch Med Wochenschr; 1978 Apr 14; 120(15):525-8. PubMed ID: 206826
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
    Schwartzkopff W, Zschiedrich M.
    Med Klin; 1978 Feb 17; 73(7):231-9. PubMed ID: 203832
    [Abstract] [Full Text] [Related]

  • 7. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
    Gustafson A.
    Postgrad Med J; 1975 Feb 17; 51(8):suppl 66-71. PubMed ID: 215983
    [No Abstract] [Full Text] [Related]

  • 8. [Use of miskleron in ischemic heart disease with differing types of hyperlipoproteinemias].
    Krivoruchenko IV, Nikul'cheva NG.
    Kardiologiia; 1976 Jul 17; 16(7):71-5. PubMed ID: 185448
    [Abstract] [Full Text] [Related]

  • 9. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
    Rouffy J, Dreux C, Goussault Y, Dakkak R, Renson FJ.
    Arzneimittelforschung; 1976 Jul 17; 26(5):901-6. PubMed ID: 183788
    [Abstract] [Full Text] [Related]

  • 10. [Different forms of hyperlipoproteinemia in diabetics (author's transl)].
    Vogt N, Englhardt A.
    Med Klin; 1975 Nov 14; 70(46):1871-7. PubMed ID: 171548
    [Abstract] [Full Text] [Related]

  • 11. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
    Weisweiler P, Schwandt P.
    Verh Dtsch Ges Inn Med; 1975 Nov 14; 83():398-401. PubMed ID: 206058
    [No Abstract] [Full Text] [Related]

  • 12. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
    Koschinsky T, Lenhard P, Gries FA, Vogelberg KH, Wolfram G, Lang PD, Vollmar J.
    Med Klin; 1977 Sep 23; 72(38):1537-43. PubMed ID: 904549
    [Abstract] [Full Text] [Related]

  • 13. A physician's guide to hyperlipidemia.
    Fredrickson DS.
    Mod Concepts Cardiovasc Dis; 1972 Jul 23; 41(7):31-6. PubMed ID: 4343098
    [No Abstract] [Full Text] [Related]

  • 14. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L, Olsson AG, Rössner S, Carlson LA.
    Postgrad Med J; 1975 Jul 23; 51(8):suppl 76-81. PubMed ID: 215986
    [Abstract] [Full Text] [Related]

  • 15. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR, Klemens UH, Vollmar LJ, Lang PD.
    Med Klin; 1978 Dec 08; 73(49):1731-7. PubMed ID: 723760
    [Abstract] [Full Text] [Related]

  • 16. [Familial hyperlipoproteinemia type III].
    Patsch JR, Patsch W, Sailer S, Braunsteiner H.
    Dtsch Med Wochenschr; 1976 Oct 29; 101(44):1612-9. PubMed ID: 185039
    [No Abstract] [Full Text] [Related]

  • 17. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
    Haacke H, Parwaresch MR, Mäder C.
    Med Klin; 1977 Jul 08; 72(27):1183-7. PubMed ID: 196168
    [Abstract] [Full Text] [Related]

  • 18. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC.
    Pharmacotherapy; 1995 Jul 08; 15(3):317-37. PubMed ID: 7667166
    [Abstract] [Full Text] [Related]

  • 19. [Interference of clofibrate in metabolic compensation in dyslipidemic diabetics].
    Gatti A, Carletta C.
    Clin Ter; 1979 Oct 15; 91(1):57-65. PubMed ID: 397871
    [No Abstract] [Full Text] [Related]

  • 20. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Oct 15; 33(5):776-9. PubMed ID: 6683558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.